We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Hikma Pharmaceuticals plc (PK) | USOTC:HKMPY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 51.914 | 50.01 | 53.08 | 45 | 16:38:30 |
LONDON, August 25, 2011 /PRNewswire/ --
Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues for the first half but maintains its full-year outlook.
The international drug developer says that political unrest in the MENA region disrupted month-on-month sales in some key countries like Egypt and Tunisia.
In an interview with financial broadcaster http://www.cantos.com, Hikma CEO Said Darwazah says that production is back to normal and that in spite of difficulties the group managed to grow the business organically by 3% in the MENA region.
While the group's Multi-Source Injectables division, which was acquired from Baxter Healthcare last year, was impacted by transaction delays, Mr Darwazah remains confident the business "will be breaking even" by the fourth quarter.
Hikma's CEO also makes clear that further acquisitions in emerging markets are in the pipeline. In the interview he reiterates full-year guidance of 7% organic growth and 20% overall business growth.
The interview and transcript are available now on http://www.cantos.com/company/Hikma%20Pharmaceuticals.
Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-(0)207-936-1372.
Copyright 2011 PR Newswire
1 Year Hikma Pharmaceuticals (PK) Chart |
1 Month Hikma Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions